Ori Gutwerg Sells 5,873 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

Key Points

• Ori Gutwerg, Senior Vice President of ANI Pharmaceuticals, sold 5,873 shares of the company's stock at an average price of $86.53, totaling approximately $508,190, which decreased his holdings by 6.53%.
• ANI Pharmaceuticals reported $1.80 EPS for the last quarter, surpassing estimates of $1.42 and achieving a 53.2% increase in quarterly revenue year-over-year.
• Stock ratings for ANI Pharmaceuticals vary, with one sell rating, one hold rating, seven buy ratings, and one strong buy rating, while the average price target stands at $84.75.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Ori Gutwerg sold 5,873 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $86.53, for a total transaction of $508,190.69. Following the completion of the sale, the senior vice president owned 84,024 shares in the company, valued at $7,270,596.72. This represents a 6.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals Trading Up 1.4%

Shares of ANIP stock traded up $1.26 on Thursday, reaching $90.00. The company had a trading volume of 604,501 shares, compared to its average volume of 623,678. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The stock has a market cap of $1.95 billion, a PE ratio of -116.88 and a beta of 0.61. The company has a 50-day moving average of $67.34 and a 200-day moving average of $64.62. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $90.23.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The business had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. During the same period in the previous year, the firm earned $1.02 EPS. ANI Pharmaceuticals's quarterly revenue was up 53.2% compared to the same quarter last year. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its position in ANI Pharmaceuticals by 68.3% during the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after acquiring an additional 64,021 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of ANI Pharmaceuticals by 53.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after purchasing an additional 3,112 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares in the last quarter. Stifel Financial Corp raised its stake in shares of ANI Pharmaceuticals by 20.4% during the 4th quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company's stock worth $466,000 after purchasing an additional 1,425 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of ANI Pharmaceuticals by 9.0% during the 4th quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company's stock worth $11,296,000 after purchasing an additional 16,820 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday. Guggenheim reissued a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright reissued a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.